InfuSystem anticipates 6% to 8% annual revenue growth as wound care expands and adjusted EBITDA margin targets low to mid-20% (NYSE:INFU)

InfuSystem (INFU) Q2 2026 earnings call recap: record $36.9M revenue, GE contract impact, Oncology/Wound Care growth, EBITDA outlook—read now.

Continue in Briflio to read, react, comment, and share.